



## Review Article

# Extracellular vesicles: Function, resilience, biomarker, bioengineering, and clinical implications

Der-Shan Sun, Hsin-Hou Chang\*

Department of Molecular  
Biology and Human Genetics,  
Tzu Chi University, Hualien,  
Taiwan

### ABSTRACT

Extracellular vesicles (EVs) have emerged as key players in intercellular communication, disease pathology, and therapeutic innovation. Initially overlooked as cellular debris, EVs are now recognized as vital mediators of cell-to-cell communication, ferrying a cargo of proteins, nucleic acids, and lipids, providing cellular resilience in response to stresses. This review provides a comprehensive overview of EVs, focusing on their role as biomarkers in disease diagnosis, their functional significance in physiological and pathological processes, and the potential of bioengineering for therapeutic applications. EVs offer a promising avenue for noninvasive disease diagnosis and monitoring, reflecting the physiological state of originating cells. Their diagnostic potential spans a spectrum of diseases, including cancer, cardiovascular disorders, neurodegenerative diseases, and infectious diseases. Moreover, their presence in bodily fluids such as blood, urine, and cerebrospinal fluid enhances their diagnostic utility, presenting advantages over traditional methods. Beyond diagnostics, EVs mediate crucial roles in intercellular communication, facilitating the transfer of bioactive molecules between cells. This communication modulates various physiological processes such as tissue regeneration, immune modulation, and neuronal communication. Dysregulation of EV-mediated communication is implicated in diseases such as cancer, immune disorders, and neurodegenerative diseases, highlighting their therapeutic potential. Bioengineering techniques offer avenues for manipulating EVs for therapeutic applications, from isolation and purification to engineering cargo and targeted delivery systems. These approaches hold promise for developing novel therapeutics tailored to specific diseases, revolutionizing personalized medicine. However, challenges such as standardization, scalability, and regulatory approval need addressing for successful clinical translation. Overall, EVs represent a dynamic frontier in biomedical research with vast potential for diagnostics, therapeutics, and personalized medicine.

**KEYWORDS:** *Bioengineering for drug delivery, Cellular resilience, Clinical therapeutics, Disease biomarker, Extracellular vesicles*

Submission : 07-Feb-2024  
Revision : 11-Mar-2024  
Acceptance : 19-Mar-2024  
Web Publication : 24-May-2024

## INTRODUCTION

Extracellular vesicles (EVs) have garnered immense interest in biomedical research due to their diverse roles in intercellular communication, disease pathogenesis, and therapeutic potential. These small membrane-bound vesicles are released by virtually all cell types into the extracellular environment and play crucial roles in mediating cell-to-cell communication [1-4]. Initially dismissed as cellular debris, EVs are now recognized as essential mediators of intercellular communication, delivering a cargo of proteins, nucleic acids, and lipids to recipient cells. This review aims to provide a comprehensive overview of the multifaceted roles of EVs, focusing on their utility as biomarkers for disease diagnosis,

their functional significance in physiological and pathological processes, and the burgeoning field of bioengineering for therapeutic applications.

As biomarkers, EVs offer a promising avenue for noninvasive disease diagnosis and monitoring. The cargo carried by EVs reflects the physiological state of the originating cells, making them valuable sources of diagnostic information [5-7]. Various studies have highlighted the

**\*Address for correspondence:** Prof. Hsin-Hou Chang,  
Department of Molecular Biology and Human Genetics, Tzu Chi  
University, 701, Zhongyang Road, Section 3, Hualien, Taiwan.  
E-mail: hhchang@mail.tcu.edu.tw

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

**For reprints contact:** WKHLRPMedknow\_reprints@wolterskluwer.com

**How to cite this article:** Sun DS, Chang HH. Extracellular vesicles: Function, resilience, biomarker, bioengineering, and clinical implications. Tzu Chi Med J 2024;36(3):251-9.

Access this article online	
<b>Quick Response Code:</b> 	<b>Website:</b> www.tcmjmed.com
	<b>DOI:</b> 10.4103/tcmj.tcmj_28_24

diagnostic potential of EVs in cancer, cardiovascular diseases, neurodegenerative disorders, and infectious diseases [8-17]. Furthermore, the stability of EVs in bodily fluids such as blood, urine, and cerebrospinal fluid enhances their utility as biomarkers, offering advantages over traditional diagnostic methods [8-16].

Beyond their diagnostic utility, EVs play essential roles in intercellular communication and modulate various physiological and pathological processes. EVs facilitate the transfer of bioactive molecules such as microRNAs (miRNAs), proteins, and lipids between cells, thereby influencing recipient cell function and behavior. In normal physiology, EVs participate in processes such as tissue regeneration, immune modulation, and neuronal communication [18-22]. When a cell faces adversity, EVs come bearing gifts of resilience. For instance, EVs carry and deliver antioxidant enzymes such as superoxide dismutases, catalase, peroxiredoxin, glutathione peroxidase, glutathione S-transferase, and thioredoxin [23], acting as molecular firefighters to quench oxidative stress, preserve cellular integrity, and facilitate resilience [23-27]. Conversely, dysregulation of EV-mediated communication has been implicated in disease pathogenesis, including cancer progression, immune disorders, and neurodegenerative diseases [1-4].

Understanding the functional significance of EVs in health and disease is therefore crucial for elucidating novel therapeutic targets and strategies.

## BIOMARKERS OF EXTRACELLULAR VESICLES

### Extracellular vesicles as diagnostic biomarkers in disease

Numerous studies have demonstrated the diagnostic potential of EVs in a wide range of diseases, including cancer, cardiovascular disorders, neurodegenerative diseases, and infectious diseases. EVs carry a diverse cargo of biomolecules, including proteins, nucleic acids, and lipids, derived from their parent cells. These molecular signatures reflect the physiological state and pathological alterations of the originating cells, making EVs valuable sources of diagnostic information. Moreover, the presence of EVs in easily accessible bodily fluids such as blood, urine, and cerebrospinal fluid enables noninvasive sampling, facilitating their utility in disease diagnosis and monitoring [8-16]. For instance, EVs present in saliva contain proteins and RNAs that function as biomarkers for oral cancer, periodontitis, and Sjögren's syndrome, aiding in their early detection and disease monitoring [28]. Moreover, EVs found in serum, plasma, and urine carry liver-specific enzymes, cytokines, and miRNAs, serving as indicators of liver injury and fibrosis,

thereby offering a noninvasive approach to diagnose and assess liver disease progression [29]. In the realm of neurodegenerative diseases, EVs in cerebrospinal fluid, plasma, and serum may encapsulate amyloid- $\beta$ , tau, and  $\alpha$ -synuclein, whose presence and levels can contribute to the diagnosis and comprehension of conditions such as Alzheimer's and Parkinson's diseases [30]. Similarly, in autoimmune diseases, EVs derived from serum, plasma, urine, and synovial fluid express autoantigens, cytokines, and miRNAs associated with these conditions, providing insights into autoimmune status and disease activity, notably in rheumatoid arthritis and systemic lupus erythematosus [31]. Moreover, EVs sourced from various bodily fluids, including serum, plasma, urine, saliva, ascites, and pleural effusion, are valuable resources for cancer diagnosis, as they can be analyzed for tumor-specific antigens and nucleic acids, facilitating early detection, diagnosis, prognosis, and monitoring of diverse cancers [32]. Here, we summarized examples on the potential use of EVs as diagnostic markers in Table 1.

### Surface marker profiling of extracellular vesicles

Profiling surface markers on EVs has become a valuable strategy for delineating EV subpopulations and understanding their functional diversity in health and disease. The surface markers, such as tetraspanins (such as CD9, CD63, and CD81), integrins, and annexins, are proposed to have a crucial role in facilitating interactions with target cells [33-35]. They serve as key identifiers for EV identification and characterization, although their presence may fluctuate depending on the EV subtype and cellular origin. Furthermore, EVs can exhibit cell- and tissue-specific markers reflective of their parent cell type or origin, thereby enhancing the complexity of their surface protein profile [33-35]. For instance, microparticles, a subset of circulating EVs, predominantly derived from platelets, exhibit high expression levels of platelet markers CD41 and P-selectin [36,37], suggesting their platelet origin. Notably, some populations of EVs exhibit elevated levels during periods of stress [17,28-32], indicating their potential suitability as markers for diseases. These surface markers are crucial for cell recognition and cargo delivery, thereby influencing EV function and biological effects. Identification of surface markers associated with specific EV subtypes provides valuable insights into their physiological roles and pathophysiological implications [38-42].

### Extracellular vesicle cargo: Molecular signatures and disease associations

The molecular cargo carried by EVs holds critical information regarding disease pathogenesis and progression. EVs from diseased cells exhibit distinct molecular signatures,

**Table 1: Potential use of extracellular vesicles as diagnostic markers**

Disease	EV source	Biomarker potential (EV cargo: Diseases)	Reference
Oral diseases	Saliva	Proteins and RNAs: Oral cancer, periodontitis, and Sjögren's syndrome	[28]
Liver failure	Serum, plasma, urine	Liver-specific enzymes, cytokines, and miRNAs: Liver injury and fibrosis	[29]
Neurodegenerative diseases	Cerebrospinal fluid, plasma, serum	Amyloid- $\beta$ , tau, $\alpha$ -synuclein: Neurodegenerative disorders	[30]
Autoimmune diseases	Serum, plasma, urine, synovial fluid	Autoantigens, cytokines, and miRNAs: Autoimmune diseases	[31]
Cancer	Serum, plasma, urine, saliva, ascites, pleural effusion	Tumor-specific antigens, and nucleic acids: Cancers	[32]

EV: Extracellular vesicles, miRNAs: MicroRNAs

including specific proteins, miRNAs, and lipids, which correlate with disease status and prognosis. Understanding the composition and dynamics of EV cargo in different disease contexts provides valuable insights into disease mechanisms and potential diagnostic markers. Moreover, the association between EV cargo and disease phenotype offers opportunities for developing targeted diagnostic approaches and personalized medicine strategies [43-47].

### **Intracellular cargo profiling of extracellular vesicles**

Intracellular cargo profiling of EVs provides crucial insights into their functional diversity and molecular signatures, allowing for the characterization of EV subtypes and their roles in health and disease. For example, the utility of EV-encapsulated miRNAs was explored as potential diagnostic markers for prostate cancer [48,49]. By analyzing miRNA profiles in EVs isolated from the blood plasma of both prostate cancer patients and healthy individuals, distinct expression patterns of certain miRNAs such as miR-140-3p, miR-150-5p, and miR-23b-3p were identified in the patient group, demonstrating promising diagnostic accuracy for prostate cancer [49]. Research also validated the presence of these EV-associated miRNAs in blood plasma, demonstrating their accurate measurability and highlighting their potential as noninvasive diagnostic and monitoring tools for cancer [48]. Accordingly, the cargo carried by EVs encompasses a diverse array of biomolecules, including proteins, nucleic acids, lipids, and metabolites, which reflect the physiological state and pathological alterations of the parent cells. By analyzing the intracellular cargo of EVs, researchers can elucidate their roles in various biological processes and disease pathogenesis [28-30,32,50-53].

## **FUNCTIONAL ROLES OF EXTRACELLULAR VESICLES**

### **Biogenesis and secretion of extracellular vesicles**

The biogenesis and secretion of EVs are intricate processes orchestrated by various cellular mechanisms [54-56]. Exosomes, small EVs ranging from 50 to 150 nm, originate from the endosomal system through the inward budding of the endosomal membrane, forming intraluminal vesicles (ILVs) within multivesicular bodies (MVBs). This process involves the endosomal sorting complex required for transport (ESCRT) machinery, responsible for sorting ubiquitinated proteins into ILVs, although ESCRT-independent pathways, involving lipids, tetraspanins, and proteins like syntenin-1, also contribute [54-56]. Once formed, MVBs are transported to the cell periphery and can fuse either with lysosomes for degradation or with the plasma membrane, facilitated by proteins such as SNAREs and Rab GTPases, leading to exosome release into the extracellular space. Microvesicles, with diameters ranging from 100 to 1000 nm, form through outward budding and fission of the plasma membrane, regulated by the cytoskeleton and involving phospholipid reorganization, including phosphatidylserine externalization and cytoskeleton-protein interactions [55]. Apoptotic bodies, typically ranging from 1 to 5  $\mu\text{m}$  in size, are discharged during the advanced stages of apoptosis, carrying cellular debris and organelles from deteriorating cells [57]. Their timely clearance by phagocytic cells is essential to prevent the

release of potentially harmful intracellular contents into the extracellular space [57], which can be identified as the sub-G1 population through flow cytometry [58-60]. Concurrently, microparticles commonly refer to circulating EVs found in the bloodstream [17,61]. These meticulously regulated mechanisms mirror the physiological state of the cell and carry significant implications for intercellular communication and the onset of disease [54-56].

### **Intercellular communication and target cell signaling modulation via extracellular vesicles**

EVs serve as potent vehicles for intercellular communication, facilitating the transfer of biomolecules between cells. By shuttling proteins, nucleic acids, and lipids, EVs enable the exchange of molecular information, influencing recipient cell behavior and function. This communication occurs locally within tissues and organs, as well as systemically throughout the body, thereby modulating various physiological processes and contributing to homeostasis [1-4].

#### *Extracellular vesicle-mediated signal induction*

EVs can induce signaling in target cells by presenting surface molecules that interact with cell-surface receptors. For example, EVs bearing ligands for receptor tyrosine kinases (RTKs) can activate signaling cascades that promote cell survival and proliferation [4]. Following are two examples of EV-mediated signal induction. (1) Interactions between surface proteins and ligands: EVs can display a diverse array of surface proteins that engage with receptors on target cells. For instance, angiopoietin-2 present on the surface of EVs has the capability to bind to the Tie2 receptor on recipient cells, thereby initiating downstream cellular signaling associated with angiogenesis, such as phosphatidylinositol 3-kinase (PI3K)/Akt/endothelial nitric oxide synthase and syndecan-4/syntenin pathways [62]. Similarly, EVs containing Toll-like receptor ligands have the ability to stimulate immune cells, prompting the secretion of cytokines and chemokines pivotal for instigating and sustaining immune responses [63]. (2) Activation of RTKs: EVs are capable of transporting ligands and/or receptors of RTKs, which, upon binding to their corresponding receptors on target cells, instigate a series of phosphorylation events [64,65]. This cascade consequently triggers various intracellular signaling pathways, including but not limited to the PI3K/Akt and MAPK pathways, which play significant roles in governing cell survival, proliferation, and differentiation [66].

#### *Transfer of functional protein and lipid components*

EVs can deliver functional proteins to recipient cells, which can directly modulate cellular signaling pathways. This includes the transfer of active enzymes that can alter the phosphorylation status of proteins within the target cell, thereby affecting signal transduction [54]. In addition, lipids are critical components in the EVs' membrane and play a crucial role in the interaction between EVs and cells [4]. For example, phosphatidylserine indirectly engages with the growth arrest-specific protein 6 (Gas6). This interaction forms the phosphatidylserine-Gas6 complex, which subsequently activates the MER tyrosine kinases located on macrophage surfaces, initiating EV uptake and inducing an anti-inflammatory phenotype [67].

### Gene regulations

EVs often contain RNA molecules, including miRNAs, messenger RNAs (mRNAs), and long noncoding RNAs. These RNAs can be delivered to recipient cells and regulate gene expression by modulating mRNA stability or translation. miRNAs, in particular, are known to play a significant role in post-transcriptional gene regulation [4,55]. In addition, epigenetic regulation is also involved in EV-mediated gene regulation [68,69].

### Role of extracellular vesicles in normal physiology and pathophysiology to persist resilience

EVs participate in various physiological processes, including tissue repair, immune regulation, and neuronal communication. In normal physiology, EVs contribute to maintaining tissue homeostasis and orchestrating cellular responses to environmental cues. Similarly, EVs have demonstrated a crucial function in maintaining cellular and physiological resilience during periods of stress [24,25]. However, dysregulation of EV-mediated signaling pathways is implicated in the pathogenesis of numerous diseases, including excessive inflammation, cancer, cardiovascular disorders, kidney pathology, neurodegenerative diseases, and pathogen invasions [18-22,70,71]. Unraveling the roles of EVs in both normal physiology and pathophysiology is critical for harnessing their therapeutic potential and developing innovative strategies for disease intervention.

## BIOENGINEERING APPROACHES FOR MANIPULATING EXTRACELLULAR VESICLES

### Isolation and purification techniques

Bioengineering advancements have led to the development of innovative methods for the isolation and purification of EVs from biological fluids and cell culture supernatants. These techniques enable the efficient extraction of EV populations with high purity and yield, facilitating downstream analyses and therapeutic applications. From traditional ultracentrifugation to emerging microfluidic-based approaches, the continuous refinement of isolation techniques enhances our ability to harness the potential of EVs for diagnostic and therapeutic purposes [72-75]. However, despite these advantages, certain limitations persist within these methods. Here, we outline the advantages and disadvantages of currently utilized EV purification methods in Table 2.

### Engineering extracellular vesicle cargo for therapeutic applications

Bioengineering strategies allow for the modification and manipulation of EV cargo, including proteins, nucleic acids, and lipids, to enhance their therapeutic efficacy. By engineering EV cargo, researchers can tailor their molecular composition and functional properties to target specific cellular pathways or disease processes. This approach holds promise for the development of novel therapeutics for a wide range of diseases, including cancer, neurodegenerative disorders, and inflammatory conditions, by exploiting the natural delivery capabilities of EVs [82-89].

### Strategies for targeted delivery and controlled release

Bioengineering approaches enable the design of EV-based delivery systems with enhanced targeting specificity and controlled release kinetics. Through surface modification and encapsulation techniques, EVs can be engineered to target specific cell types or tissues and deliver therapeutic payloads with precision. Moreover, bioengineered EVs can be engineered to respond to external stimuli, allowing for the spatiotemporal control of cargo release. These strategies hold great potential for overcoming biological barriers, improving drug delivery efficiency, and minimizing off-target effects in therapeutic applications [90-95].

### Biomedical applications of biosimulating artificial extracellular vesicles

Artificial EVs represent a cutting-edge approach in biomedical research, offering versatile platforms for mimicking the natural functions of EVs with enhanced controllability and tenability [96-98]. These synthetic vesicles are engineered to replicate key characteristics of native EVs, including their size, morphology, and surface properties, while providing advantages in cargo loading, targeting specificity, and therapeutic efficacy. By modulating the lipid composition, surface modifications, and cargo content of artificial EVs, researchers can tailor their properties for a wide range of biomedical applications, from drug delivery and disease diagnosis to regenerative medicine [96-98].

For instance, artificial EVs have been extensively explored for drug delivery applications, leveraging their biocompatibility, biodegradability, and cargo-loading capacity. These synthetic vesicles can encapsulate a variety of therapeutic agents, including small molecules, nucleic acids, and proteins, offering precise control over drug release kinetics and biodistribution [96-99]. By modifying the surface of liposomes with targeting ligands or antibodies, researchers can augment their specificity for afflicted tissues or cells, thereby enhancing therapeutic outcomes while minimizing off-target effects [96-99]. For instance, lectin-conjugated liposomes, such as P-selectin, E-selectin, L-selectin, and galectins, demonstrate the ability to deliver drugs specifically to inflamed and injured cells, enabling precise drug delivery to individual dying cells at a single-cell resolution [99]. These engineered synthetic vesicles can be tailored to encapsulate hydrophobic or hydrophilic drugs, imaging agents, or contrast agents, facilitating multimodal imaging and targeted therapy across various disease scenarios. Overall, the biomedical utilization of artificial EVs shows significant promise in advancing personalized medicine approaches and addressing unmet clinical needs [96-99].

## FUTURE PERSPECTIVES AND CHALLENGES

### Emerging technologies and trends in extracellular vesicle research

The rapid evolution of technologies, such as single-vesicle analysis, advanced imaging techniques, and high-throughput sequencing, promises to unveil new insights into the biology and functions of EVs. Moreover, the integration of multi-omics approaches and systems biology strategies will



**Table 2: Benefits and drawbacks of currently used extracellular vesicle isolation and purification methods**

Purification method	Principle	Advantages	Disadvantages	Reference
Density gradient centrifugation	Separating EVs from other components based on their buoyant density by using a density gradient medium	High purity, preserves EV integrity and function	Time-consuming, low yield, requires large sample volume, may alter EV composition	[76,77]
Size exclusion chromatography	Separating EVs from other components based on their size by using a porous matrix	High purity, preserves EV integrity and function, compatible with different sample types	Low yield, requires large sample volume, may lose small EVs	[76,78]
Ultrafiltration	Separating EVs from other components based on their size by using a semipermeable membrane	High yield, fast, scalable, compatible with different sample types	Low purity, may damage EVs, may cause membrane fouling	[76-78]
Precipitation	Precipitating EVs from the solution by using organic solvents, polymers, or salts	High yield, fast, scalable, compatible with different sample types	Low purity, may damage EVs, may alter EV composition, may introduce contaminants	[76,78]
Immunoaffinity capture	Capturing EVs from the solution by using antibodies against specific EV surface markers	High specificity, high purity, enables subpopulation analysis	Low yield, expensive, requires prior knowledge of EV markers, may cause cross-reactivity or steric hindrance	[76,78,79]
Microfluidics	Manipulating EVs in microscale channels by using various physical or biochemical forces	High throughput, high purity, high sensitivity, enables multiplex analysis, preserves EV integrity and function	Expensive, complex, requires specialized equipment and expertise, may introduce contaminants	[80,81]

EV: Extracellular vesicle

enable the comprehensive characterization of EV cargo and their roles in health and disease [100-103]. Additionally, the emergence of organoid and organ-on-a-chip models offers sophisticated platforms for studying EV-mediated intercellular communication and disease mechanisms in physiologically relevant contexts [104-106].

### Clinical translation and therapeutic potential of engineered extracellular vesicles

The clinical translation of engineered EVs holds immense promise for revolutionizing personalized medicine and therapeutic interventions. Engineered EVs offer targeted drug delivery, immunomodulatory effects, and regenerative potential for various diseases, including wound healing, cancer, neurodegenerative disorders, and inflammatory conditions [107,108]. However, the consistent isolation of EVs poses technical challenges, compounded by the intricate analyses necessary for their efficient study, which may hinder the utilization of pure EV populations as reliable biomarkers. Although biomarker identification holds significance for enhancing the diagnosis, monitoring, prediction, and prognosis of the diseases, prioritizing reproducibility and user-friendliness is paramount [109]. Moreover, the transition of EV-based therapies from experimental stages to practical clinical applications encounters obstacles concerning scalability, standardization of manufacturing processes, and regulatory approval. Overcoming these challenges will be essential for unlocking the therapeutic promise of engineered EVs in clinical contexts. Based on existing literature, we outline potential future directions of EV research in Table 3.

### Considerations in extracellular vesicle-based therapeutics

With the advancement of EV-based therapeutics, regulatory considerations become increasingly important [119]. Regulatory frameworks need to be established to ensure the safety, efficacy, and quality of engineered EV products. In addition, the ethical implications of modifying EV cargo and

engineering EVs for specific therapeutic purposes should be carefully evaluated. Collaborative efforts among researchers, clinicians, and regulators are essential to navigate these complex ethical and regulatory landscapes and facilitate the responsible development and deployment of EV-based therapeutics [119].

### CONCLUSION

EVs represent dynamic mediators of intercellular communication and hold immense potential in biomedical research and clinical applications. This review provides a comprehensive overview of the multifaceted roles of EVs, emphasizing their utility as biomarkers for disease diagnosis, their functional significance in physiological and pathological processes, and the burgeoning field of bioengineering for therapeutic applications. The diagnostic potential of EVs as biomarkers offers a promising avenue for noninvasive disease diagnosis and monitoring. Their unique molecular cargo, reflective of the physiological state of originating cells, makes EVs valuable sources of diagnostic information. Moreover, the stability of EVs in bodily fluids enables their utility in disease diagnosis across a wide range of conditions, from cancer to infectious diseases. In addition to their diagnostic utility, EVs play essential roles in intercellular communication, influencing various physiological and pathological processes. Their ability to transfer biologically active cargo between cells modulates recipient cell behavior and function, impacting processes such as tissue regeneration, immune modulation, and disease progression. Dysregulation of EV-mediated communication is implicated in numerous diseases, highlighting the importance of understanding their functional roles in health and disease. Bioengineering approaches offer exciting opportunities for manipulating EVs for therapeutic applications. From isolation and purification techniques to engineering EV cargo and designing targeted delivery systems, bioengineering strategies enable precise control over EV properties and functions.

**Table 3: Potential future focuses of extracellular vesicle research**

Future focus	Description	Reference
EV biogenesis and secretion	Understanding the molecular mechanisms and regulation of EV formation and release from different cell types and under different conditions	[110,111]
EV cargo and function	Identifying the composition and function of EVs in various physiological and pathological processes, and elucidating the factors that determine the sorting and transfer of EV cargo	[110-112]
EV heterogeneity and subpopulations	Characterizing the diversity and specificity of EVs based on their origin, size, shape, surface markers, and molecular content, and developing methods to isolate and analyze EV subpopulations	[113]
EV detection and quantification	Developing novel and standardized methods and technologies to detect and quantify EVs in different samples, and establishing reliable and reproducible EV quality control and validation criteria	[114]
EV engineering and modification	Improving the stability, specificity, and delivery efficiency of EVs, and modifying their molecular content and surface properties, using various methods such as genetic manipulation, chemical modification, and physical loading	[112,115]
EV-based therapeutics and drug delivery	Exploring the potential of EVs as natural and biocompatible carriers of therapeutic agents or immunostimulatory molecules, and optimizing their targeting and biodistribution	[110,112,115,116]
EV-based biomarkers and diagnostics	Exploiting the diagnostic and prognostic value of EVs as sources of disease-specific biomolecules, and developing sensitive and specific EV-based assays and biosensors	[110]
EV-based inter-kingdom communication	Investigating the role of EVs in mediating the interactions between different kingdoms of life, such as plants, animals, fungi, and bacteria, and their implications for health and disease	[55,117,118]

EV: Extracellular vesicle

These advancements hold great promise for developing novel therapeutics for a wide range of diseases, revolutionizing personalized medicine and therapeutic interventions. Looking ahead, emerging technologies, clinical translation, and regulatory considerations will shape the future landscape of EV research and applications. Continued interdisciplinary collaboration and innovation are essential for overcoming challenges and harnessing the full potential of EVs in biomedical research and clinical practice. By leveraging the versatility and adaptability of EVs, we can pave the way for transformative advancements in diagnostics, therapeutics, and personalized medicine.

#### Data availability statement

Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.

#### Acknowledgments

The authors would like to express their gratitude to the Experimental Animal Center and Core Facility Center at Tzu Chi University for their invaluable assistance with animal care, confocal microscopy, and flow cytometry experiments.

#### Financial support and sponsorship

This work is supported by research funding from National Science and Technology Council, Taiwan (104-2320-B-320-009-MY3, 107-2311-B-320-002-MY3, 111-2320-B320-006-MY3, 112-2320-B-320-007), and Tzu Chi Medical Foundation (TCMMP104-06, TCMMP108-04, TCMMP 111-01, TCAS111-02, TCAS-112-02, TCAS113-04, TCRD112-033, TCRD113-041). The funders have no role in the study design; in data collection, analysis, and interpretation; in writing the report; and in the decision to submit the article for publication.

#### Conflicts of interest

Dr. Hsin-Hou Chang, the editorial board member at *Tzu Chi Medical Journal*, played no role in the peer review process or decision to publish this article. The other author declared no conflicts of interest in writing this paper.

## REFERENCES

- Sarkar S, Patranabis S. Emerging role of extracellular vesicles in intercellular communication in the brain: Implications for neurodegenerative diseases and therapeutics. *Cell Biochem Biophys* 2024. doi: 10.1007/s12013-024-01221-z.
- Liu W, Jin M, Chen Q, Li Q, Xing X, Luo Y, et al. Insight into extracellular vesicles in vascular diseases: Intercellular communication role and clinical application potential. *Cell Commun Signal* 2023;21:310.
- Petroni D, Fabbri C, Babboni S, Menichetti L, Basta G, Del Turco S. Extracellular vesicles and intercellular communication: Challenges for *in vivo* molecular imaging and tracking. *Pharmaceutics* 2023;15:1639.
- Liu YJ, Wang C. A review of the regulatory mechanisms of extracellular vesicles-mediated intercellular communication. *Cell Commun Signal* 2023;21:77.
- Kirchner B, Buschmann D, Paul V, Pfaffl MW. Postprandial transfer of colostral extracellular vesicles and their protein and miRNA cargo in neonatal calves. *PLoS One* 2020;15:e0229606.
- Santos MF, Rappa G, Karbanová J, Vanier C, Morimoto C, Corbeil D, et al. Anti-human CD9 antibody Fab fragment impairs the internalization of extracellular vesicles and the nuclear transfer of their cargo proteins. *J Cell Mol Med* 2019;23:4408-21.
- Bouvy C, Wannez A, Laloy J, Chatelain C, Dogné JM. Transfer of multidrug resistance among acute myeloid leukemia cells via extracellular vesicles and their microRNA cargo. *Leuk Res* 2017;62:70-6.
- Gutiérrez-Fernández M, de la Cuesta F, Tallón A, Cuesta I, Fernández-Fournier M, Laso-García F, et al. Potential roles of extracellular vesicles as biomarkers and a novel treatment approach in multiple sclerosis. *Int J Mol Sci* 2021;22:9011.
- Taha HB, Bogoniewski A. Analysis of biomarkers in speculative CNS-enriched extracellular vesicles for parkinsonian disorders: A comprehensive systematic review and diagnostic meta-analysis. *J Neurol* 2024;271:1680-707.
- Qu Y, Huang X, Zhang W, He X, Chen Z, Zhang Y, et al. Differentially expressed miR-127, miR-150, and miR-145 in serum extracellular vesicles are novel diagnostic biomarkers of unstable angina. *Cardiovasc Diagn Ther* 2023;13:866-78.
- Xu X, Iqbal Z, Xu L, Wen C, Duan L, Xia J, et al. Brain-derived extracellular vesicles: Potential diagnostic biomarkers for central nervous system diseases. *Psychiatry Clin Neurosci* 2024;78:83-96.

12. Jnana A, Sadiya SS, Satyamoorthy K, Murali TS. Extracellular vesicles in bacterial and fungal diseases – Pathogenesis to diagnostic biomarkers. *Virulence* 2023;14:2180934.
13. Odaka H, Hiemori K, Shimoda A, Akiyoshi K, Tateno H. CD63-positive extracellular vesicles are potential diagnostic biomarkers of pancreatic ductal adenocarcinoma. *BMC Gastroenterol* 2022;22:153.
14. Wang Y, Wang Y, Chen Y, Hua Y, Xu L, Zhu M, et al. Circulating MicroRNAs from plasma small extracellular vesicles as potential diagnostic biomarkers in pediatric epilepsy and drug-resistant epilepsy. *Front Mol Neurosci* 2022;15:823802.
15. Martin-Ventura JL, Roncal C, Orbe J, Blanco-Colio LM. Role of extracellular vesicles as potential diagnostic and/or therapeutic biomarkers in chronic cardiovascular diseases. *Front Cell Dev Biol* 2022;10:813885.
16. Leggio L, Paternò G, Vivarelli S, Falzone GG, Giachino C, Marchetti B, et al. Extracellular vesicles as novel diagnostic and prognostic biomarkers for Parkinson's disease. *Aging Dis* 2021;12:1494-515.
17. Sun DS, Chang YW, Kau JH, Huang HH, Ho PH, Tzeng YJ, et al. Soluble P-selectin rescues mice from anthrax lethal toxin-induced mortality through PSGL-1 pathway-mediated correction of hemostasis. *Virulence* 2017;8:1216-28.
18. Grange C, Dalmaso A, Cortez JJ, Spokeviciute B, Bussolati B. Exploring the role of urinary extracellular vesicles in kidney physiology, aging, and disease progression. *Am J Physiol Cell Physiol* 2023;325:C1439-50.
19. Zheng T. A review of the roles of specialized extracellular vesicles, migrasomes, and exosomes in normal cell physiology and disease. *Med Sci Monit* 2023;29:e940118.
20. Lee Y, Kim JH. The emerging roles of extracellular vesicles as intercellular messengers in liver physiology and pathology. *Clin Mol Hepatol* 2022;28:706-24.
21. Yates AG, Pink RC, Erdbrügger U, Siljander PR, Dellar ER, Pantazi P, et al. In sickness and in health: The functional role of extracellular vesicles in physiology and pathology *in vivo*: Part II: Pathology: Part II: Pathology. *J Extracell Vesicles* 2022;11:e12190.
22. Yates AG, Pink RC, Erdbrügger U, Siljander PR, Dellar ER, Pantazi P, et al. In sickness and in health: The functional role of extracellular vesicles in physiology and pathology *in vivo*: Part I: Health and normal physiology: Part I: Health and normal physiology. *J Extracell Vesicles* 2022;11:e12151.
23. Bodega G, Alique M, Puebla L, Carracedo J, Ramírez RM. Microvesicles: ROS scavengers and ROS producers. *J Extracell Vesicles* 2019;8:1626654.
24. Beckner ME, Konkright WR, Sahu A, Mi Q, Clemens ZJ, Martin BJ, et al. Utility of extracellular vesicles as a potential biological indicator of physiological resilience during military operational stress. *Physiol Rep* 2022;10:e15219.
25. Alharbi MG, Lee SH, Abdelazim AM, Saadeldin IM, Abomughaid MM. Role of extracellular vesicles in compromising cellular resilience to environmental stressors. *Biomed Res Int* 2021;2021:9912281.
26. Makrygianni EA, Chrousos GP. Extracellular vesicles and the stress system. *Neuroendocrinology* 2023;113:120-67.
27. De Maio A. Extracellular heat shock proteins, cellular export vesicles, and the stress observation system: A form of communication during injury, infection, and cell damage. It is never known how far a controversial finding will go! Dedicated to Ferruccio Ritossa. *Cell Stress Chaperones* 2011;16:235-49.
28. Wu J, Liu G, Jia R, Guo J. Salivary extracellular vesicles: Biomarkers and Beyond in Human Diseases. *Int J Mol Sci* 2023;24:17328.
29. Lu W, Tang H, Li S, Bai L, Chen Y. Extracellular vesicles as potential biomarkers and treatment options for liver failure: A systematic review up to March 2022. *Front Immunol* 2023;14:1116518.
30. Raghav A, Singh M, Jeong GB, Giri R, Agarwal S, Kala S, et al. Extracellular vesicles in neurodegenerative diseases: A systematic review. *Front Mol Neurosci* 2022;15:1061076.
31. Xu K, Liu Q, Wu K, Liu L, Zhao M, Yang H, et al. Extracellular vesicles as potential biomarkers and therapeutic approaches in autoimmune diseases. *J Transl Med* 2020;18:432.
32. Ciferri MC, Quarto R, Tasso R. Extracellular vesicles as biomarkers and therapeutic tools: From pre-clinical to clinical applications. *Biology (Basel)* 2021;10:359.
33. Jankovičová J, Sečová P, Michalková K, Antalíková J. Tetraspanins, more than markers of extracellular vesicles in reproduction. *Int J Mol Sci* 2020;21:7568.
34. Hsu MT, Wang YK, Tseng YJ. Exosomal proteins and lipids as potential biomarkers for lung cancer diagnosis, prognosis, and treatment. *Cancers (Basel)* 2022;14:732.
35. Thakur A, Ke X, Chen YW, Motallebejad P, Zhang K, Lian Q, et al. The mini player with diverse functions: Extracellular vesicles in cell biology, disease, and therapeutics. *Protein Cell* 2022;13:631-54.
36. Italiano JE Jr., Mairuhu AT, Flaumenhaft R. Clinical relevance of microparticles from platelets and megakaryocytes. *Curr Opin Hematol* 2010;17:578-84.
37. Taus F, Meneguzzi A, Castelli M, Minuz P. Platelet-derived extracellular vesicles as target of antiplatelet agents. What is the evidence? *Front Pharmacol* 2019;10:1256.
38. Giovanazzi A, van Herwijnen MJ, Kleinjan M, van der Meulen GN, Wauben MH. Surface protein profiling of milk and serum extracellular vesicles unveils body fluid-specific signatures. *Sci Rep* 2023;13:8758.
39. Shimoda A, Akiyoshi K. Surface glycan profiling of extracellular vesicles by lectin microarray and glycoengineering for control of cellular interactions. *Pharm Res* 2023;40:795-800.
40. Manouchehri Doulabi E, Fredolini C, Gallini R, Löf L, Shen Q, Ikebuchi R, et al. Surface protein profiling of prostate-derived extracellular vesicles by mass spectrometry and proximity assays. *Commun Biol* 2022;5:1402.
41. Cavallaro S, Horak J, Hååg P, Gupta D, Stiller C, Sahu SS, et al. Label-free surface protein profiling of extracellular vesicles by an electrokinetic sensor. *ACS Sens* 2019;4:1399-408.
42. Belov L, Hallal S, Matic K, Zhou J, Wissmueller S, Ahmed N, et al. Surface profiling of extracellular vesicles from plasma or ascites fluid using dotscan antibody microarrays. *Methods Mol Biol* 2017;1619:263-301.
43. Hánělová K, Raudenská M, Masářík M, Balvan J. Protein cargo in extracellular vesicles as the key mediator in the progression of cancer. *Cell Commun Signal* 2024;22:25.
44. Teli P, Vaidya A, Kale V. Signal transduction pathways alter the molecular cargo of extracellular vesicles: Implications in regenerative medicine. *Regen Med* 2023;18:935-44.
45. Fischetti F, Poli L, De Tommaso M, Paolicelli D, Greco G, Cataldi S. The role of exercise parameters on small extracellular vesicles and microRNAs cargo in preventing neurodegenerative diseases. *Front Physiol* 2023;14:1241010.
46. Mastrototaro L, Roden M. The effects of extracellular vesicles and their cargo on metabolism and its adaptation to physical exercise in insulin resistance and type 2 diabetes. *Proteomics* 2023; 23: e2300078.
47. Rädler J, Gupta D, Zickler A, Andaloussi SE. Exploiting the biogenesis of extracellular vesicles for bioengineering and therapeutic cargo loading. *Mol Ther* 2023;31:1231-50.
48. Paiva RM, Zauli DA, Neto BS, Brum IS. Urinary microRNAs expression in prostate cancer diagnosis: A systematic review. *Clin Transl Oncol* 2020;22:2061-73.
49. Cruz-Burgos M, Cortés-Ramírez SA, Losada-García A, Morales-Pacheco M, Martínez-Martínez E, Morales-Montor JG, et al. Unraveling the role of EV-derived miR-150-5p in prostate cancer metastasis and its association with high-grade Gleason scores: Implications for diagnosis. *Cancers (Basel)* 2023;15:4148.

50. McNamee N, de la Fuente LR, Santos-Martinez MJ, O'Driscoll L. Proteomics profiling identifies extracellular vesicles' cargo associated with tumour cell induced platelet aggregation. *BMC Cancer* 2022;22:1023.
51. Hamdi M, Cañon-Beltrán K, Mazzarella R, Cajas YN, Leal CL, Gutierrez-Adan A, et al. Characterization and profiling analysis of bovine oviduct and uterine extracellular vesicles and their miRNA cargo through the estrous cycle. *FASEB J* 2021;35:e22000.
52. Sehrawat TS, Arab JP, Liu M, Amrollahi P, Wan M, Fan J, et al. Circulating extracellular vesicles carrying sphingolipid cargo for the diagnosis and dynamic risk profiling of alcoholic hepatitis. *Hepatology* 2021;73:571-85.
53. Whiteside TL. Profiling of plasma-derived extracellular vesicles cargo for diagnosis of pancreatic malignancy. *Ann Transl Med* 2017;5:501.
54. Jin Y, Ma L, Zhang W, Yang W, Feng Q, Wang H. Extracellular signals regulate the biogenesis of extracellular vesicles. *Biol Res* 2022;55:35.
55. Fang Y, Wang Z, Liu X, Tyler BM. Biogenesis and biological functions of extracellular vesicles in cellular and organismal communication with microbes. *Front Microbiol* 2022;13:817844.
56. Krylova SV, Feng D. The machinery of exosomes: Biogenesis, release, and uptake. *Int J Mol Sci* 2023;24:1337.
57. Yu L, Zhu G, Zhang Z, Yu Y, Zeng L, Xu Z, et al. Apoptotic bodies: Bioactive treasure left behind by the dying cells with robust diagnostic and therapeutic application potentials. *J Nanobiotechnology* 2023;21:218.
58. Attallah AM, Tabll AA, Salem SF, El-Sadany M, Ibrahim TA, Osman S, et al. DNA ploidy of liver biopsies from patients with liver cirrhosis and hepatocellular carcinoma: A flow cytometric analysis. *Cancer Lett* 1999;142:65-9.
59. Lin GL, Chang HH, Lien TS, Chen PK, Chan H, Su MT, et al. Suppressive effect of dengue virus envelope protein domain III on megakaryopoiesis. *Virulence* 2017;8:1719-31.
60. Tsai CL, Sun DS, Su MT, Lien TS, Chen YH, Lin CY, et al. Suppressed humoral immunity is associated with dengue nonstructural protein NS1-elicited anti-death receptor antibody fractions in mice. *Sci Rep* 2020;10:6294.
61. Hrachovinová I, Cambien B, Hafezi-Moghadam A, Kappelmayer J, Camphausen RT, Widom A, et al. Interaction of P-selectin and PSGL-1 generates microparticles that correct hemostasis in a mouse model of hemophilia A. *Nat Med* 2003;9:1020-5.
62. Ju R, Zhuang ZW, Zhang J, Lanahan AA, Kyriakides T, Sessa WC, et al. Angiotensin-2 secretion by endothelial cell exosomes: Regulation by the phosphatidylinositol 3-kinase (PI3K)/Akt/endothelial nitric oxide synthase (eNOS) and syndecan-4/syntenin pathways. *J Biol Chem* 2014;289:510-9.
63. Papayannakos CJ, DeVoti JA, Israr M, Alsudani H, Bonagura V, Steinberg BM. Extracellular vesicles produced by primary human keratinocytes in response to TLR agonists induce stimulus-specific responses in antigen-presenting cells. *Cell Signal* 2021;83:109994.
64. Zanetti-Domingues LC, Bonner SE, Martin-Fernandez ML, Huber V. Mechanisms of action of EGFR tyrosine kinase receptor incorporated in extracellular vesicles. *Cells* 2020;9:2505.
65. Zanetti-Domingues LC, Bonner SE, Iyer RS, Martin-Fernandez ML, Huber V. Cooperation and Interplay between EGFR signalling and extracellular vesicle biogenesis in cancer. *Cells* 2020;9:2639.
66. Zhang N, Li Y. Receptor tyrosine kinases: Biological functions and anticancer targeted therapy. *MedComm (2020)* 2023;4:e446.
67. Graham DK, DeRyckere D, Davies KD, Earp HS. The TAM family: Phosphatidylserine sensing receptor tyrosine kinases gone awry in cancer. *Nat Rev Cancer* 2014;14:769-85.
68. Qian Z, Shen Q, Yang X, Qiu Y, Zhang W. The role of extracellular vesicles: An epigenetic view of the cancer microenvironment. *Biomed Res Int* 2015;2015:649161.
69. Di Liegro CM, Schiera G, Di Liegro I. Extracellular vesicle-associated RNA as a carrier of epigenetic information. *Genes (Basel)* 2017;8:240.
70. Lien TS, Sun DS, Wu CY, Chang HH. Exposure to dengue envelope protein domain III induces Nlrp3 inflammasome-dependent endothelial dysfunction and hemorrhage in mice. *Front Immunol* 2021;12:617251.
71. Hung SC, Ke LC, Lien TS, Huang HS, Sun DS, Cheng CL, et al. Nanodiamond-induced thrombocytopenia in mice involve P-selectin-dependent Nlrp3 inflammasome-mediated platelet aggregation, pyroptosis and apoptosis. *Front Immunol* 2022;13:806686.
72. Chiva-Blanch G. Methods of isolation and purification of extracellular vesicles from different biological matrixes: Special issue at a glance. *J Vis Exp* 2023; 192: 64963.
73. Rao KU, Godaly G. Isolation and purification of mycobacterial extracellular vesicles (EVs). *Methods Mol Biol* 2023;2674:55-60.
74. Xue Y, Huang X, Ou Z, Wu Y, Li Q, Huang X, et al. Isolation and purification of bacterial extracellular vesicles from human feces using density gradient centrifugation. *J Vis Exp* 2023; 199: 65574.
75. Zhang C, Yang X, Jiang T, Yan C, Xu X, Chen Z. Tissue-derived extracellular vesicles: Isolation, purification, and multiple roles in normal and tumor tissues. *Life Sci* 2023;321:121624.
76. Mortezaee K, Majidpoor J, Fathi F. Extracellular vesicle isolation, purification and evaluation in cancer diagnosis. *Expert Rev Mol Med* 2022;24:e41.
77. Zhang Q, Jeppesen DK, Higginbotham JN, Franklin JL, Coffey RJ. Comprehensive isolation of extracellular vesicles and nanoparticles. *Nat Protoc* 2023;18:1462-87.
78. Zheng X, Ai H, Qian K, Li G, Zhang S, Zou Y, et al. Small extracellular vesicles purification and scale-up. *Front Immunol* 2024;15:1344681.
79. Masaki K, Ahmed AB, Ishida T, Mikami Y, Funabashi H, Hirota R, et al. Chromatographic purification of small extracellular vesicles using an affinity column for phospholipid membranes. *Biotechnol Lett* 2023;45:1457-66.
80. Havers M, Broman A, Lenshof A, Laurell T. Advancement and obstacles in microfluidics-based isolation of extracellular vesicles. *Anal Bioanal Chem* 2023;415:1265-85.
81. Abreu CM, Costa-Silva B, Reis RL, Kundu SC, Caballero D. Microfluidic platforms for extracellular vesicle isolation, analysis and therapy in cancer. *Lab Chip* 2022;22:1093-125.
82. Jiang C, Zhang J, Wang W, Shan Z, Sun F, Tan Y, et al. Extracellular vesicles in gastric cancer: Role of exosomal lncRNA and microRNA as diagnostic and therapeutic targets. *Front Physiol* 2023;14:1158839.
83. Yang L, Hao Y, Boeckmans J, Rodrigues RM, He Y. Immune cells and their derived microRNA-enriched extracellular vesicles in nonalcoholic fatty liver diseases: Novel therapeutic targets. *Pharmacol Ther* 2023;243:108353.
84. Takahashi Y, Takakura Y. Extracellular vesicle-based therapeutics: Extracellular vesicles as therapeutic targets and agents. *Pharmacol Ther* 2023;242:108352.
85. Eguchi A, Iwasa M, Nakagawa H. Extracellular vesicles in fatty liver disease and steatohepatitis: Role as biomarkers and therapeutic targets. *Liver Int* 2023;43:292-8.
86. Huang X, Lan Y, Shen J, Chen Z, Xie Z. Extracellular vesicles in bone homeostasis: Emerging mediators of osteoimmune interactions and promising therapeutic targets. *Int J Biol Sci* 2022;18:4088-100.
87. Manfredi M, Williams E, Cho WC, Falasca M. Editorial: Recent advances in *in vitro* and *in vivo* multi-omics analyses of extracellular vesicles: Therapeutic targets and biomarkers. *Front Mol Biosci* 2021;8:784436.
88. Tamura T, Yoshioka Y, Sakamoto S, Ichikawa T, Ochiya T. Extracellular vesicles in bone metastasis: Key players in the tumor microenvironment and promising therapeutic targets. *Int J Mol Sci* 2020;21:6680.
89. Kogure A, Yoshioka Y, Ochiya T. Extracellular Vesicles in Cancer Metastasis: Potential as Therapeutic Targets and Materials. *Int J Mol Sci* 2020;21:4463.
90. Wang S, Wang R, Chen J, Yang B, Shu J, Cheng F, et al. Controlled



- extracellular vesicles release from aminoguanidine nanoparticle-loaded polylysine hydrogel for synergistic treatment of spinal cord injury. *J Control Release* 2023;363:27-42.
91. Krivitsky V, Krivitsky A, Mantella V, Ben-Yehuda Greenwald M, Sankar DS, Betschmann J, et al. Ultrafast and controlled capturing, loading, and release of extracellular vesicles by a portable microstructured electrochemical fluidic device. *Adv Mater* 2023;35:e2212000.
  92. Banerjee A, Lino M, Jesus C, Ribeiro Q, Abrunhosa A, Ferreira L. Imaging platforms to dissect the *in vivo* communication, biodistribution and controlled release of extracellular vesicles. *J Control Release* 2023;360:549-63.
  93. Bari E, Di Gravina GM, Scocozza F, Perteghella S, Frongia B, Tengattini S, et al. Silk fibroin bioink for 3D printing in tissue regeneration: Controlled release of MSC extracellular vesicles. *Pharmaceutics* 2023;15:383.
  94. Yoshizaki K, Nishida H, Tabata Y, Jo JI, Nakase I, Akiyoshi H. Controlled release of canine MSC-derived extracellular vesicles by cationized gelatin hydrogels. *Regen Ther* 2023;22:1-6.
  95. Man K, Barroso IA, Brunet MY, Peacock B, Federici AS, Hoey DA, et al. Controlled release of epigenetically-enhanced extracellular vesicles from a GelMA/nanoclay composite hydrogel to promote bone repair. *Int J Mol Sci* 2022;23:832.
  96. Rosso G, Cauda V. Biomimicking extracellular vesicles with fully artificial ones: A rational design of EV-BIOMIMETICS toward effective theranostic tools in nanomedicine. *ACS Biomater Sci Eng* 2023;9:5924-32.
  97. Li YJ, Wu JY, Liu J, Xu W, Qiu X, Huang S, et al. Artificial exosomes for translational nanomedicine. *J Nanobiotechnology* 2021;19:242.
  98. Zhao J, Yang J, Jiao J, Wang X, Zhao Y, Zhang L. Biomedical applications of artificial exosomes for intranasal drug delivery. *Front Bioeng Biotechnol* 2023;11:1271489.
  99. Chang HH, Sun DS. Vesicles comprising lectins expressed on the surface and methods of use thereof to deliver an agent to autophagic and apoptotic cells. In: US10584154b2. Assignee: Tzu-Chi University; 2020.
  100. Clarke E, Varela L, Jenkins RE, Lozano-Andrés E, Cywińska A, Przewozny M, et al. Proteome and phospholipidome interrelationship of synovial fluid-derived extracellular vesicles in equine osteoarthritis: An exploratory 'multi-omics' study to identify composite biomarkers. *Biochem Biophys Rep* 2024;37:101635.
  101. Lu X, Li Y, Li Y, Zhang X, Shi J, Feng H, et al. Advances of multi-omics applications in hepatic precancerous lesions and hepatocellular carcinoma: The role of extracellular vesicles. *Front Mol Biosci* 2023;10:1114594.
  102. Liu Y, Li Y, Zeng T. Multi-omics of extracellular vesicles: An integrative representation of functional mediators and perspectives on lung disease study. *Front Bioinform* 2023;3:1117271.
  103. Garikipati VN, Shoja-Taheri F, Davis ME, Kishore R. Extracellular vesicles and the application of system biology and computational modeling in cardiac repair. *Circ Res* 2018;123:188-204.
  104. Zhang Y, Lu A, Zhuang Z, Zhang S, Liu S, Chen H, et al. Can organoid model reveal a key role of extracellular vesicles in tumors? A comprehensive review of the literature. *Int J Nanomedicine* 2023;18:5511-27.
  105. Thompson RE, Bouma GJ, Hollinshead FK. The roles of extracellular vesicles and organoid models in female reproductive physiology. *Int J Mol Sci* 2022;23:3186.
  106. Kim MH, van Noort D, Sung JH, Park S. Organ-on-a-chip for studying gut-brain interaction mediated by extracellular vesicles in the gut microenvironment. *Int J Mol Sci* 2021;22:13513.
  107. Liao Y, Zhang Z, Ouyang L, Mi B, Liu G. Engineered extracellular vesicles in wound healing: Design, paradigms, and clinical application. *Small* 2024;20:e2307058.
  108. Kim H, Kim D, Nam H, Moon S, Kwon YJ, Lee JB. Engineered extracellular vesicles and their mimetics for clinical translation. *Methods* 2020;177:80-94.
  109. Couch Y. Challenges associated with using extracellular vesicles as biomarkers in neurodegenerative disease. *Expert Rev Mol Diagn* 2023;23:1091-105.
  110. Gurunathan S, Kang MH, Kim JH. A comprehensive review on factors influences biogenesis, functions, therapeutic and clinical implications of exosomes. *Int J Nanomedicine* 2021;16:1281-312.
  111. van Niel G, Carter DR, Clayton A, Lambert DW, Raposo G, Vader P. Challenges and directions in studying cell-cell communication by extracellular vesicles. *Nat Rev Mol Cell Biol* 2022;23:369-82.
  112. Han Y, Jones TW, Dutta S, Zhu Y, Wang X, Narayanan SP, et al. Overview and update on methods for cargo loading into extracellular vesicles. *Processes (Basel)* 2021;9:356.
  113. Bobis-Wozowicz S, Marbán E. Editorial: Extracellular vesicles as next generation therapeutics. *Front Cell Dev Biol* 2022;10:919426.
  114. Hartjes TA, Mytnyk S, Jenster GW, van Steijn V, van Royen ME. Extracellular vesicle quantification and characterization: Common methods and emerging approaches. *Bioengineering (Basel)* 2019;6:7.
  115. Rhim WK, Kim JY, Lee SY, Cha SG, Park JM, Park HJ, et al. Recent advances in extracellular vesicle engineering and its applications to regenerative medicine. *Biomater Res* 2023;27:130.
  116. Jin S, Lv Z, Kang L, Wang J, Tan C, Shen L, et al. Next generation of neurological therapeutics: Native and bioengineered extracellular vesicles derived from stem cells. *Asian J Pharm Sci* 2022;17:779-97.
  117. Ambrosone A, Barbulova A, Cappelletta E, Cillo F, De Palma M, Ruocco M, et al. Plant extracellular vesicles: Current landscape and future directions. *Plants (Basel)* 2023;12:4141.
  118. Rizzo J, Rodrigues ML, Janbon G. Extracellular vesicles in fungi: Past, present, and future perspectives. *Front Cell Infect Microbiol* 2020;10:346.
  119. Cheng K, Kalluri R. Guidelines for clinical translation and commercialization of extracellular vesicles and exosomes based therapeutics. *Extracell Vesicle* 2023;2:1-9.